ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

Abstract Number: 1772

Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program
Abstract Number: 0916

Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Abstract Number: 1974

Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures
Abstract Number: 1165

Validation of Healthcare Claims Algorithms for Identification of Herpes Zoster Among Children with Autoimmune/Autoinflammatory Disease
Abstract Number: 0721

Validation of New Antirheumatic Drug Use as a Proxy for Increased JIA Disease Activity
Abstract Number: 0161

Validation of Patient-reported Outcomes (PRO) Lung Questionnaires for Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease
Abstract Number: 0427

Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis
Abstract Number: 0249

Validation of the SIMPLE Index for Disease Activity of Systemic Lupus Erythematosus in Chinese Patients
Abstract Number: 0094

Validation Study of Proposed Diagnostic Criteria for Sympathetic Joint Effusion
Abstract Number: 1985

Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis
Abstract Number: 1963

Variation in Quality of Care Among Patient Sociodemographic Groups in RISE Practices
Abstract Number: 0716

Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Abstract Number: 0152

Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
Abstract Number: 1929

Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review
Abstract Number: 1447

Vitamin D Deficiency Enhances Antiphospholipid Antibody-Mediated Thrombosis in a Passive Immunization Mouse Model
Abstract Number: 1802

Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
Abstract Number: 0790

Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects
Abstract Number: 0633

Vitamin D Serum Status in a Cohort of COVID-19 Patients
Abstract Number: 0862

Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].